

**Table S1.**

| Full name                                                    | Short name | Biochemical characteristics             | Functional characteristics                                              | Biomarker pitfall           | Citations                                    |
|--------------------------------------------------------------|------------|-----------------------------------------|-------------------------------------------------------------------------|-----------------------------|----------------------------------------------|
| precursor pro-hormone of ADM–mid regional pro-adrenomedullin | MR-proADM  | longer half-life than ADM               | prognostic value in disease                                             | no known action by itself   | Marino R. et al. 10.1186/cc13731.            |
| bioactive adrenomedullin                                     | bioADM     | active, short-lived circulating peptide | associated with severe organ dysfunction and an elevated mortality risk | less used in the literature | Laterre PF et al. 10.1007/s00134-021-06537-5 |
| plasma adrenomedullin                                        | ADM        | vasodilatory peptide                    | prognostic value in disease                                             | short half-life             | Marino R. et al. 10.1186/cc13731.            |

## References

1. Marino R, Struck J, Maisel AS, Magrini L, Bergmann A, Di Somma S. Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. *Crit Care*. 2014;18(1): R34. Published 2014 Feb 17. doi:10.1186/cc13731
2. Laterre PF, Pickkers P, Marx G, et al. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial. *Intensive Care Med*. 2021;47(11):1284-1294. doi:10.1007/s00134-021-06537-5